These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 32818544

  • 1. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
    Yu T, An Q, Cao XL, Yang H, Cui J, Li ZJ, Xiao G.
    Life Sci; 2020 Nov 01; 260():118294. PubMed ID: 32818544
    [Abstract] [Full Text] [Related]

  • 2. The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway.
    Li Y, Yan W, Qin Y, Zhang L, Xiao S.
    Int J Mol Sci; 2024 Jun 12; 25(12):. PubMed ID: 38928176
    [Abstract] [Full Text] [Related]

  • 3. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
    Chen J, Shao R, Li F, Monteiro M, Liu JP, Xu ZP, Gu W.
    Clin Exp Pharmacol Physiol; 2015 Dec 12; 42(12):1317-26. PubMed ID: 26399781
    [Abstract] [Full Text] [Related]

  • 4. Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway.
    Zhu Y, Zhong Y, Long X, Zhu Z, Zhou Y, Ye H, Zeng X, Zheng X.
    Pharm Biol; 2019 Dec 12; 57(1):412-423. PubMed ID: 31230505
    [Abstract] [Full Text] [Related]

  • 5. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS, Du J, Fan YJ, Liu FJ, Cao LL, Liang N, Xu DG, Zhang JD.
    Oncotarget; 2016 Nov 22; 7(47):76827-76839. PubMed ID: 27765907
    [Abstract] [Full Text] [Related]

  • 6. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q, Wang C, Han X, Yang G, Ge Z, Zhang G.
    Biochem Biophys Res Commun; 2018 Sep 18; 503(4):2333-2339. PubMed ID: 29964008
    [Abstract] [Full Text] [Related]

  • 7. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, Song L, Xu R, Ma Y, Cai S, Tang X.
    Biomed Res Int; 2021 Sep 18; 2021():5556306. PubMed ID: 33987439
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
    Hu Y, Zhang K, Zhu X, Zheng X, Wang C, Niu X, Jiang T, Ji X, Zhao W, Pang L, Qi Y, Li F, Li L, Xu Z, Gu W, Zou H.
    Int J Nanomedicine; 2021 Sep 18; 16():2173-2186. PubMed ID: 33758505
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
    Liu Y, Bi T, Wang Z, Wu G, Qian L, Gao Q, Shen G.
    Apoptosis; 2016 Dec 18; 21(12):1398-1407. PubMed ID: 27671687
    [Abstract] [Full Text] [Related]

  • 17. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL, Wang LK, Yang DD, Qu M, Yang YJ, Guo F, Han L, Xue J.
    J Cell Biochem; 2018 Feb 18; 119(2):2356-2367. PubMed ID: 28884839
    [Abstract] [Full Text] [Related]

  • 18. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.